Predictive value of a serum tumor biomarkers scoring system for clinical stage II/III rectal cancer with neoadjuvant chemoradiotherapy

Table 3 Univariate analysis of factors affecting disease-free survival

Characteristic	HR (95%CI)	P value
Pre-NCRT CEA (< 3.55/> 3.55)	0.391 (0.178-0.859)	0.019
Pre-NCRT CA19-9 (< 19.01/> 19.01)	0.413 (0.213-0.802)	0.009
Sex (male/female)	0.466 (0.213-1.023)	0.057
Pathological TNM stage (0-I/II-III)	0.302 (0.132-0.690)	0.005
Pathological vascular invasion (absent/present)	0.571 (0.175-1.863)	0.353
Pathological lymphatic invasion (absent/present)	0.435 (0.154-1.231)	0.117
Pathological perineural invasion (absent/present)	0.595 (0.279-1.265)	0.177
Pathological CRM (negative/positive)	0.657 (0.158-2.738)	0.564
NSTB score (0-1/2)	0.391 (0.203-0.751)	0.005

NCRT: Neoadjuvant chemoradiotherapy; CEA: Carcinoembryonic antigen; CA19-9: Cancer antigen 19-9; TNM: Tumor, node and metastasis; CRM: Circumferential resection margin; NSTB: Novel serum tumor biomarker score.